Jeffery P Struewing

List of Publications by Year
in descending order

100	29,265	44069	32842
papers	citations	48 h-index	100 g-index

102	102	102	40070
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	1.9	16
2	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
3	The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science, 2015, 348, 648-660.	12.6	4,659
4	Effect of predicted protein-truncating genetic variants on the human transcriptome. Science, 2015, 348, 666-669.	12.6	252
5	Meeting Research Needs with Postmortem Biospecimen Donation: Summary of Recommendations for Postmortem Recovery of Normal Human Biospecimens for Research. Biopreservation and Biobanking, 2013, 11, 77-82.	1.0	13
6	The Genotype-Tissue Expression (GTEx) project. Nature Genetics, 2013, 45, 580-585.	21.4	6,815
7	No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. Breast Cancer Research and Treatment, 2011, 125, 169-173.	2.5	26
8	The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Medical Genomics, 2011, 4, 13.	1.5	618
9	Fine scale mapping of the breast cancer 16q12 locus. Human Molecular Genetics, 2010, 19, 2507-2515.	2.9	68
10	Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma. PLoS ONE, 2009, 4, e4812.	2.5	53
11	Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics, 2009, 18, 1131-1139.	2.9	84
12	FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Human Molecular Genetics, 2009, 18, 1692-1703.	2.9	110
13	Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists. Breast Cancer Research and Treatment, 2009, 118, 177-184.	2.5	18
14	Thyroid Nodules, Polymorphic Variants in DNA Repair andRET-Related Genes, and Interaction with Ionizing Radiation Exposure from Nuclear Tests in Kazakhstan. Radiation Research, 2009, 171, 77-88.	1.5	38
15	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics, 2008, 9, 14.	2.7	31
16	Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. International Journal of Cancer, 2008, 122, 177-182.	5.1	58
17	Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976â€“1999. European Journal of Medical Genetics, 2008, 51, 141-147.	1.3	20
18	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genetics, 2008, 4, e1000054.	3.5	315

#	Article	IF	Citations
19	Breast Cancer Risk Polymorphisms and Interaction with Ionizing Radiation among U.S. Radiologic Technologists. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2007-2011.	2.5	32
20	Papillary Thyroid Cancer and Polymorphic Variants in TSHR- and RET-Related Genes: a Nested Case-Control Study within a Cohort of U.S. Radiologic Technologists. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 174-177.	2.5	28
21	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	2.5	30
22	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Research, 2007, 17, 1111-1117.	5.5	24
23	Polymorphisms in Apoptosis- and Proliferation-Related Genes, Ionizing Radiation Exposure, and Risk of Breast Cancer among U.S. Radiologic Technologists. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2000-2007.	2.5	45
24	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
25	The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genetics, 2007, 8, 68.	2.7	8
26	A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics, 2007, 39, 352-358.	21.4	591
27	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	27.8	2,165
28	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Human Genetics, 2006, 119, 376-388.	3.8	144
29	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genetic Epidemiology, 2006, 30, 48-61.	1.3	17
30	TheATMmissense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Human Mutation, 2006, 27, 538-544.	2.5	56
31	BRCA1/2 testing in hereditary breast and ovarian cancer families III: Risk perception and screening. American Journal of Medical Genetics, Part A, 2006, 140A, 2198-2206.	1.2	26
32	Quantitation of DNA in buccal cell samples collected in epidemiological studies. Biomarkers, 2006, 11, 472-479.	1.9	14
33	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 76-79.	2.5	26
34	Candidate Single Nucleotide Polymorphism Selection using Publicly Available Tools: A Guide for Epidemiologists. American Journal of Epidemiology, 2006, 164, 794-804.	3.4	49
35	BRCA1/2 testing in hereditary breast and ovarian cancer families II: Impact on relationships. American Journal of Medical Genetics, Part A, 2005, 133A, 165-169.	1.2	36
36	Skewed X chromosome inactivation and early-onset breast cancer. Journal of Medical Genetics, 2005, 43, 48-53.	3.2	15

#	Article	IF	Citations
37	Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up ofBRCA1Mutation Carriers. Journal of Clinical Oncology, 2005, 23, 8629-8635.	1.6	138
38	DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 586, 173-188.	1.7	41
39	Genomic Approaches to Identifying Breast Cancer Susceptibility Factors. Breast Disease, 2004, 19, 3-9.	0.8	5
40	Prospective risk of cancer in CDKN2A germline mutation carriers. Journal of Medical Genetics, 2004, 41, 421-424.	3.2	69
41	XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. British Journal of Cancer, 2004, 90, 497-502.	6.4	68
42	BRCA1 and sex ratio. European Journal of Human Genetics, 2004, 12, 663-667.	2.8	7
43	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer, 2004, 4, 9.	2.6	73
44	BRCA1/2 testing in hereditary breast and ovarian cancer families: Effectiveness of problemâ€solving training as a counseling intervention. American Journal of Medical Genetics Part A, 2004, 130A, 221-227.	2.4	40
45	Heterogeneity of risk for melanoma and pancreatic and digestive malignancies. Cancer, 2004, 101, 2809-2816.	4.1	33
46	CHEK2:1100delC and female breast cancer in the United States. International Journal of Cancer, 2004, 112, 541-543.	5.1	20
47	Frequency of BRCA Mutations in Primary Peritoneal Carcinoma in Israeli Jewish Women. Gynecologic Oncology, 2003, 88, 58-61.	1.4	35
48	Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecologic Oncology, 2003, 89, 494-498.	1.4	61
49	Mutational analysis of theBRCA1-interacting genesZNF350/ZBRK1andBRIP1/BACH1amongBRCA1andBRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Human Mutation, 2003, 22, 121-128.	2.5	49
50	Performance of high-throughput DNA quantification methods. BMC Biotechnology, 2003, 3, 20.	3.3	81
51	CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene, 2003, 22, 4444-4448.	5.9	29
52	Gynecologic Surgeries and Risk of Ovarian Cancer in Women With BRCA1 and BRCA2 Ashkenazi Founder Mutations: An Israeli Population-Based Case-Control Study. Journal of the National Cancer Institute, 2003, 95, 1072-1078.	6.3	96
53	Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. Journal of the National Cancer Institute, 2003, 95, 1251-1252.	6.3	9
54	A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. Journal of Medical Genetics, 2003, 40, 787-792.	3.2	82

#	Article	IF	Citations
55	The HER2 I655V Polymorphism and Breast Cancer Risk in Ashkenazim. Epidemiology, 2003, 14, 694-700.	2.7	27
56	HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. Nucleic Acids Research, 2002, 30, 5213-5221.	14.5	34
57	Breast Cancer Risk in Ashkenazi BRCA1/2 Mutation Carriers: Effects of Reproductive History. Epidemiology, 2002, 13, 255-261.	2.7	35
58	Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors. Journal of Clinical Oncology, 2002, 20, 463-466.	1.6	175
59	Efficiency of DNA pooling to estimate joint allele frequencies and measure linkage disequilibrium. Genetic Epidemiology, 2002, 22, 94-102.	1.3	39
60	A natural history of melanomas and dysplastic nevi. Cancer, 2002, 94, 3192-3209.	4.1	137
61	A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. British Journal of Cancer, 2001, 85, 527-530.	6.4	28
62	Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2001, 345, 235-240.	27.0	370
63	Psychosocial factors predictingBRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. American Journal of Medical Genetics Part A, 2000, 93, 257-263.	2.4	124
64	Patients with Double Primary Tumors in the Breast and Ovaryâ€" Clinical Characteristics and BRCA1â€"2 Mutations Status. Gynecologic Oncology, 2000, 79, 74-78.	1.4	18
65	Genotype-Phenotype Relationships in U.S. Melanoma-Prone Families With CDKN2A and CDK4 Mutations. Journal of the National Cancer Institute, 2000, 92, 1006-1010.	6.3	172
66	A Single Genetic Origin for the G101W CDKN2A Mutation in 20 Melanoma-Prone Families. American Journal of Human Genetics, 2000, 67, 311-319.	6.2	80
67	Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 1999, 91, 259-263.	6.3	75
68	Re: Effect of BRCA1 and BRCA2 on the Association Between Breast Cancer Risk and Family History. Journal of the National Cancer Institute, 1999, 91, 1250-1251.	6.3	5
69	The Prevalence of Common BRCA1 and BRCA2 Mutations among Ashkenazi Jews. American Journal of Human Genetics, 1999, 64, 963-970.	6.2	204
70	Founder BRCA1/2 Mutations among Male Patients with Breast Cancer in Israel. American Journal of Human Genetics, 1999, 65, 1800-1802.	6.2	50
71	Histopathologic Features of Ovaries at Increased Risk for Carcinoma. International Journal of Gynecological Pathology, 1999, 18, 151-157.	1.4	47
72	The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nature Genetics, 1998, 20, 62-65.	21.4	176

#	Article	IF	Citations
73	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. Breast Journal, 1998, 4, 9-12.	1.0	4
74	Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet, The, 1998, 352, 1337-1339.	13.7	325
75	Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families. American Journal of Human Genetics, 1998, 62, 676-689.	6.2	2,662
76	The Kin-Cohort Study for Estimating Penetrance. American Journal of Epidemiology, 1998, 148, 623-630.	3.4	134
77	Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations. Journal of the National Cancer Institute, 1998, 90, 1138-1145.	6.3	652
78	BRCA1 in Special Populations. Breast Disease, 1998, 10, 71-75.	0.8	6
79	The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi Jews. New England Journal of Medicine, 1997, 336, 1401-1408.	27.0	2,135
80	Automated Detection of Prevalent Mutations inBRCA1andBRCA2Genes, Using a Fluorogenic PCR Allelic Discrimination Assay. Genetic Testing and Molecular Biomarkers, 1997, 1, 171-180.	1.7	14
81	BRCA1 mutations in young women with breast cancer. Lancet, The, 1996, 347, 1493.	13.7	39
82	Melanoma-prone kindreds with p16 mutation are also at risk of pancreatic cancer. Advances in Anatomic Pathology, 1996, 3, 250.	4.3	0
83	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics, 1996, 14, 188-190.	21.4	375
84	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Medicine, 1996, 2, 1179-1183.	30.7	294
85	Prevalence of Toxoplasma gondii Antibodies in U.S. Military Recruits in 1989: Comparison with Data Published in 1965. Clinical Infectious Diseases, 1996, 23, 1182-1183.	5.8	47
86	The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genetics, 1995, 11, 198-200.	21.4	625
87	Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16^{INK4}Mutations. New England Journal of Medicine, 1995, 333, 970-975.	27.0	608
88	Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. Genomics, 1995, 25, 238-247.	2.9	62
89	Localisation of the breast-ovarian cancer susceptibility gene (BRCAl) on 17q12â€“21 to an interval of î¹ºIcM. Genes Chromosomes and Cancer, 1994, 10, 71-76.	2.8	18
90	Germline p16 mutations in familial melanoma. Nature Genetics, 1994, 8, 15-21.	21.4	1,170

#	Article	IF	Citations
91	Interpreting a single antistreptolysin o test: A comparison of the â€œupper limit of normalâ€•and likelihood ratio methods. Journal of Clinical Epidemiology, 1993, 46, 1181-1185.	5.0	17
92	Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination. Clinical Infectious Diseases, 1993, 17, 66-73.	5.8	176
93	The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits.. American Journal of Public Health, 1993, 83, 1717-1720.	2.7	101
94	Genetic epidemiology of epithelial ovarian cancer. Cancer, 1993, 71, 566-572.	4.1	56
95	Tuberculosis infection among young adults entering the US Navy in 1990. Archives of Internal Medicine, 1993, 153, 211-216.	3.8	3
96	Oral Erythromycin Prophylaxis against Streptococcus pyogenes Infection in Penicillin-Allergic Military Recruits: A Randomized Clinical Trial. Journal of Infectious Diseases, 1992, 166, 162-165.	4.0	15
97	Efficacy of Hepatitis B Vaccination in Primary School Children from a Village Endemic for Schistosoma mansoni. Journal of Infectious Diseases, 1992, 166, 265-268.	4.0	17
98	HyperendemicStreptococcus pyogenesInfection despite Prophylaxis with Penicillin G Benzathine. New England Journal of Medicine, 1991, 325, 92-97.	27.0	52
99	AN EPIDEMIC OF RESPIRATORY COMPLAINTS EXACERBATED BY MASS PSYCHOGENIC ILLNESS IN A MILITARY RECRUIT POPULATION. American Journal of Epidemiology, 1990, 132, 1120-1129.	3.4	29
100	Sonographic studies of schoolchildren in a village endemic for Schistosoma mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 69-73.	1.8	41